Glenmark Pharmaceuticals Limited has uploaded the transcript of its first quarter fiscal year 2027 earnings call to its official website, offering investors a comprehensive written record of management’s discussion on financial performance. The conference call took place on August 3, 2026, covering the quarter ended June 30, 2026. This disclosure ensures transparency and allows stakeholders to review the detailed discussion on operational and financial metrics presented during the event.

The company submitted this information to the National Stock Exchange of India Limited and BSE Limited in compliance with regulatory requirements. Specifically, the disclosure was made pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely dissemination of material information to listed entities’ shareholders and the broader market.

Disciplinary Compliance Details

Glenmark Pharmaceuticals Limited confirmed that the transcript is hosted at a specific URL on its corporate domain. The reference number for this communication is 41/26-27. The submission was digitally signed by Rashmi Khandelwal, the Company Secretary & Compliance Officer, on August 5, 2026. Her ACS number is 28839. The company’s registered office is located in Mumbai, and it operates under CIN L24299MH1977PLC019982.

Accessing the Transcript

Investors and analysts can access the transcript directly via the link provided in the exchange filing. The document is titled "Glenmark-Earnings-Aug03-2026-Revised.pdf" and is stored in the Financials/Quarterly section of the Glenmark Pharmaceuticals website. This direct access mechanism aligns with best practices for investor relations, ensuring that all market participants have equal opportunity to review management’s perspective on the quarter’s results without delay.

Glenmark Pharmaceuticals has laid out a comprehensive growth and financial strategy, projecting steady expansion across its key markets while maintaining disciplined cost management. The company expects its India business to grow at 12% to 15%, supported by the introduction of new products including Aumolertinib and Trastuzumab Rezatecan. On the balance sheet side, the company is targeting approximately 115 net working capital days and zero gross debt, signalling a focus on financial discipline. In a further update, the company has revealed that approximately 25% of its total sales are derived from the US market, with quarterly US sales expected to surpass $100 million.

US Market Performance and Outlook

Glenmark has disclosed that the US market accounts for approximately 25% of its total sales, underscoring the significance of this geography to its overall business. The company is predicting a strong increase in US sales going forward, with quarterly US sales projected to exceed $100 million. Respiratory products have been identified as a key contributor to the anticipated recovery and growth momentum in North America.

India Business Outlook

The India segment is expected to be a key growth driver, with the company projecting 12% to 15% growth backed by new product launches. Aumolertinib and Trastuzumab Rezatecan are among the notable additions to the portfolio that are expected to support this trajectory. These launches are anticipated to strengthen Glenmark's positioning in the domestic pharmaceutical market.

Operating Margins and Cost Management

Despite cost pressures arising from geopolitical issues, Glenmark expects to maintain operating margins between 21% and 22% for FY27. The company plans to achieve this by optimising its product and geographical mix, demonstrating a proactive approach to managing external headwinds. The following table summarises the key financial and operational targets outlined by the company:

International Markets: Europe

In Europe, Glenmark expects high single-digit growth for the current year, with ambitions to achieve double-digit growth the following year, driven by increased branded launches. The company also projects over 18% yearly growth when excluding 2001 deferred income, reflecting broad-based international performance.

R&D Investment and IGI Pipeline

Glenmark's research and development spending is expected to remain in the range of approximately 7% to 8%. The company has also outlined plans for IGI investments of approximately $70 million over the next two to three years, which will include clinical trials for 2301 Phase 1. These investments reflect the company's commitment to building a robust pipeline to support future growth across its business segments.